ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2524

Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs

Alvin F. Wells1, Yvonne C. Lee2, Namita Tundia3, Jessica Suboticki3, Kun Chen3, Alan Friedman3 and Vibeke Strand4, 1Rheumatology and Immunotherapy Center, Franklin, WI, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3AbbVie Inc., North Chicago, IL, 4Stanford University, Palo Alto, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: patient-reported outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although treatment with csDMARDs and bDMARDs can lead to remission in patients with RA, many patients still experience pain and morning (AM) stiffness, which have a meaningful negative impact on quality of life. We assessed the effect of upadacitinib (UPA), a selective JAK-1 inhibitor, alone or in combination with csDMARDs vs background therapy on pain and AM stiffness in patients with active RA who had an inadequate response (IR) to csDMARDs or bDMARDs.

Methods: Data from the SELECT-NEXT (NCT02675426), SELECT-BEYOND (NCT02706847), and SELECT-MONO (NCT02706951) randomized controlled trials were analyzed. Patients in NEXT (csDMARD-IR) and BEYOND (bDMARD-IR) received UPA (15 mg or 30 mg daily) or PBO with csDMARDs for 12 weeks (wks), and those in the MONO trial (csDMARD-IR) received UPA monotherapy (15 mg or 30 mg daily) or MTX (mean dose: 17 mg/wk) for 14 wks. Pain and duration of AM stiffness were assessed through 12/14 wks. Least squares mean (LSM) percent changes from baseline (BL) to wk 12/14 were based on mixed effect repeated measures models. Percentages of patients reporting ≥50% improvement in pain, those reporting no pain or mild pain (absolute pain score <20), and those reporting AM stiffness <15 minutes were determined at each timepoint for UPA (both doses), PBO, or MTX; comparisons between groups used Cochran-Mantel-Haenszel tests with prior bDMARDs use as stratification factor.

Results: Across all 3 trials, statistically significant LSM percent changes from BL to wks 12/14 in pain and duration of AM stiffness were reported in both UPA dose groups (except AM stiffness duration in BEYOND) compared with PBO or MTX groups (Figures 1 and 2). Across trials, significantly (p<0.05) more UPA-treated patients (15 mg: 41–51%, 30 mg: 42–56%) reported ≥50% improvement in pain at wks 12/14 compared with PBO or MTX (19–25%). Significantly (p<0.05) more UPA-treated patients (15 mg: 30-36%, 30 mg: 36-44%) reported no pain or mild pain at wks 12/14 compared with PBO or MTX (14–15%). The percentage of UPA-treated patients (15 mg: 26–42%, 30 mg: 29–43%) reporting AM stiffness duration <15 minutes at wks 12/14 was approximately twice that in PBO or MTX (15–23%) groups. Across all measures, improvements in UPA-treated patients were evident as early as wk 2.

Conclusion: Treatment with UPA in combination with csDMARDs vs PBO resulted in significant and rapid improvements in pain and AM stiffness across different RA patient populations including csDMARD-IR and bDMARD-IR. Similar improvements vs MTX were reported when UPA was administered as monotherapy.

Medical writing services provided by Joann Hettasch (Fishawack Group, US) and funded by AbbVie.


Disclosure: A. F. Wells, AbbVie Inc., 2, 5,AbbVie Inc., 2; Y. C. Lee, Pfizer, Inc., 2,Eli Lilly and Co., 6; N. Tundia, AbbVie Inc., 3,AbbVie Inc., 1; J. Suboticki, AbbVie Inc., 3,AbbVie Inc., 1; K. Chen, AbbVie Inc., 3,AbbVie Inc., 1; A. Friedman, AbbVie Inc., 3,AbbVie Inc., 1; V. Strand, AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, EMD Serono, Genentech/Roche, GSK, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB, 5.

To cite this abstract in AMA style:

Wells AF, Lee YC, Tundia N, Suboticki J, Chen K, Friedman A, Strand V. Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/effect-of-upadacitinib-on-pain-and-morning-stiffness-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-or-biologic-disease-modifying-anti-rheumatic-drugs/. Accessed May 26, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-upadacitinib-on-pain-and-morning-stiffness-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-or-biologic-disease-modifying-anti-rheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.